Your session is about to expire
← Back to Search
Tenecteplase for Ischemic Stroke (ALLY Trial)
ALLY Trial Summary
This trial studies if giving clot-dissolving drugs after a type of stroke treatment is safe and effective. Patients will be followed for 3 months.
- Ischemic Stroke
- Stroke
ALLY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ALLY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had an allergic reaction to TNK before.You have a known blood clotting problem or a deficiency in blood clotting factors.You had a score of 4 or higher on a scale that measures ability before getting sick.You have had bleeding in the brain or your head CT scan shows a score of 6 or lower.Your blood platelet count is less than 100,000.You have a known tendency to bleed easily.You have a tumor or growth that is pushing on nearby structures.You had a stroke more than 6 hours ago, and a special brain scan doesn't show the right conditions for this study.You have had a specific type of procedure to remove a blood clot in your brain with a certain number of attempts, and the blood vessels are still blocked in a way that cannot be fixed with the same procedure.Your high blood pressure is very severe and not getting better with treatment.You have had a stroke caused by a sudden lack of blood flow to the brain in the past 60 days.You are suspected to have a bacterial infection in your heart or other parts of your body.There is a concern that you may have a tear in the main blood vessel leading from your heart.You have a tumor in your brain.You are currently taking a specific type of blood thinner called a NOAC, or your blood clotting test (INR) is too high.You are currently taking two types of blood-thinning medications for a specific medical procedure.You are currently on dialysis or need dialysis.You have a serious medical condition and are expected to live less than 6 months.You are between 18 and 85 years old.You have had a specific type of stroke in the front part of your brain and are getting a treatment called mechanical thrombectomy within 24 hours of when the stroke symptoms started.You have been treated within 6 hours of the last time you were known to be well, and your ASPECTS score is greater than 6.
- Group 1: Intra-arterial Tenecteplase
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical research accommodate geriatric patient participation?
"This research requires that participants be aged 18 to 85. There are 5 trials for those younger than eighteen and 367 studies dedicated to senior citizens over 65 years old."
For which demographic is this research endeavor open?
"This medical trial is welcoming 20 participants that have suffered a stroke and are between 18-85 years old."
Has the FDA sanctioned Intra-arterial Tenecteplase?
"Our team at Power rated the safety of Intra-arterial Tenecteplase as a 2, due to the Phase 2 status indicating some evidence for its security but no data confirming efficacy."
What further research has been conducted regarding the efficacy of Intra-arterial Tenecteplase?
"Currently, there are 11 active clinical trials on Intra-arterial Tenecteplase with 9 of them in the final trial phase. Despite most of these studies being based around Beijing, a total of 260 research centres across the world are conducting investigations into this medication."
How many participants are involved in the research endeavor?
"Affirmative. The information posted on clinicaltrials.gov verifies that this medical study is actively recruiting participants, with the initial posting occurring on March 15th of 2022 and the most recent update dated April 19th 2023. This trial requires a total of 20 patients from 1 location to participate."
Are there still openings available for enrollees in this medical study?
"Affirmative. According to clinicaltrials.gov, recruitment for this trial is currently underway with the initial posting on March 15th 2022 and its most recent update being April 19th 2023. The study wishes to enroll a total of 20 patients from one medical centre."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger